Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sound waves vs. belly fat: a new weapon against abdominal obesity?

NCT ID NCT07686601

Disease control Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study investigates whether applying sound waves (extracorporeal shockwave therapy) to the abdomen, alongside a low-calorie diet and aerobic exercise, can reduce abdominal fat and improve metabolic health in adults with abdominal obesity. Researchers will measure changes in waist size, blood sugar, cholesterol, and liver health over 12 weeks. The goal is to see if this non-invasive approach offers an extra benefit beyond diet and exercise alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
extracorporeal shockwave therapy
What this could lead to
If it works, this could offer a non-invasive way to reduce belly fat and improve markers of metabolic health like blood sugar and cholesterol.
What could go wrong
This is a small, early-stage trial with no blinding or placebo group, so results may be due to the diet and exercise alone. The shockwave therapy may have no added benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: This study will be delimited by: 1. Age \> 18years old. 2. All of them suffered from abdominal obesity. 3. All have waist/ hip ratio of \> 0.85 and their waist circumference \> 90 cm. Exclusion criteria: Patients who had the following features will be excluded from the study: 1. Patients with diabetes mellitus, heart and/ or vascular, renal, hepatic, pulmonary, neurological, psychological, and or mental disorders are excluded. 2. Patients who had autoimmune diseases were excluded. 3. Patients with hypertension, metal or electronic implants were excluded. 4. Patients, who have intra-abdominal mesh and/ or unrepaired abdominal hernia were excluded. 5. Patients who have cancer were excluded. 6. Patients who have scars, open lesions and wounds at treatment area were excluded. 7. Patients who have any intervention to lose weight or body contouring within the last 6 months (diet, exercise or body contouring devices) were excluded. 8. Patients who received pharmacological drugs for controlling obesity were excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Abdominal obesity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome Obesity, Abdominal

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Abdominal obesity Abdominal obesity in young and middle aged adults Abdominal obesity-metabolic syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shebin ElKom Teaching Hospital

    Shibīn al Kawm, Menofyia, 11432, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.